Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook

Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48

April 21, 2015 4:01 PM EDT

THOUSAND OAKS, Calif., April 21, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2015. Key results include:

Total revenues increased 11 percent versus the first quarter of 2014 to $5,033 million, with 12 percent product sales growth driven primarily by Enbrel® (etanercept), Prolia® (denosumab), EPOGEN® (epoetin alfa), Sensipar® (cinacalcet) and XGEVA® (denosumab). Unfavorable changes in foreign exchange rates impacted total revenue and product sales growth by 2 percentage points. Adjusted EPS grew 33 percent versus the first quarter of 2014 to $2.48 driven by higher revenues and lower operating expenses. Adjusted operating... More